Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

1. Dolutegravir/lamivudine (Dovato) - Human Immunodeficiency Virus type 1 (HIV-1)

Dolutegravir/lamivudine (Dovato) - Human Immunodeficiency Virus type 1 (HIV-1) Final Appraisal Recommendation Advice No: 0220 – February 2020 Dolutegravir/lamivudine (Dovato ® ) 50 mg/300 mg film-coated tablets Limited submission by ViiV Healthcare UK Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3659), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal (...) Recommendation (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Dolutegravir/lamivudine (Dovato ® ) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults

2020 All Wales Medicines Strategy Group

2. Financial education for HIV?vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence Full Text available with Trip Pro

Financial education for HIV?vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence Financial education for HIV‐vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence - Lee - 2020 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Financial education for HIV (...) of Use. Shareable Link Use the link below to share a full-text version of this article with your friends and colleagues. Copy URL Share a link Share on 1 Children and youth are defined as those between 0 and 24 years by UN and UNICEF definitions ( , , retrieved on November 15, 2017). HIV is the leading cause of youth mortality in Africa, and the second cause of death among young people worldwide (UNAIDS, ; WHO, ). Young girls are particularly vulnerable (Fleischman & Peck, ), accounting for 20

2020 Campbell Collaboration

3. The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP

limited to English articles published since 2015. Reference lists of identified articles were also searched. The search yielded 1,343 references from which 28 were included. Reference list Newman DR, Rahman MM, Brantley A, Peterman TA. Rates of new human immunodeficiency virus (HIV) diagnoses after reported sexually transmitted infection in women in Louisiana, 2000–2015: Implications for HIV prevention. Clinical Infectious Diseases. 2019. Peterman TA, Newman DR, Maddox L, Schmitt K, Shiver S. Risk (...) . 1999;20(3):295–9. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: Results from a ten-year study. American Journal of Epidemiology. 1997;146(4):350–7. Calabrese SK, Willie TC, Galvao RW, Tekeste M, Dovidio JF, Safon CB, et al. Current US guidelines for prescribing HIV pre-exposure prophylaxis (PrEP) disqualify many women who are at risk and motivated to use PrEP. Journal of Acquired Immune Deficiency Syndromes

2020 Ontario HIV Treatment Network

4. What methods have been effective in promoting uptake of Pre-exposure prophylaxis (PrEP) among individuals at high risk of HIV, excluding men who have sex with men

What methods have been effective in promoting uptake of Pre-exposure prophylaxis (PrEP) among individuals at high risk of HIV, excluding men who have sex with men Knowledge & Library Services (KLS) Evidence Briefing What methods have been effective in promoting uptake of Pre- exposure prophylaxis (PrEP) among individuals at high risk of HIV, excluding men who have sex with men (MSM), in developed cities comparable to London Nicola Pearce-Smith March 15 th 2019 What methods have been effective (...) in promoting uptake of PrEP among individuals at high risk of HIV KLS Evidence Briefing March 19th 2019 Research question This briefing summarises the evidence on the uptake of PrEP amongst high risk groups such as women, transgender, black Africans, sex workers, drug addicts and young people, from January 1 st 2017 to February 28 th 2019. Key messages • Barriers to PrEP uptake identified across all risk groups were safety, side effects, lack of knowledge, medication regimen, socioeconomic factors, stigma

2020 Public Health England - Evidence Briefings

5. HIV self-testing in high-income settings: Acceptability, potential benefits and harms, issues related to linkage to care, interventions to increase HIV self-testing

. Human immunodeficiency virus testing practices and interest in self-testing options among young, Black men who have sex with men in North Carolina. Sexually Transmitted Diseases. 2016;43(9):587–93. Rosales-Statkus ME, de la Fuente L, Fernandez-Balbuena S, Figueroa C, Fernandez-Lopez L, Hoyos J, et al. Approval and potential use of over-the-counter HIV self-tests: The opinion of participants in a street based HIV rapid testing program in Spain. AIDS & Behavior. 2015;19(3):472–84. Sharma A, Sullivan (...) and bisexual men. AIDS & Behavior. 2014;18(12):2485–95. Udeagu CN, Shah S, Molochevski M. Men who have sex with men seek timely human immunodeficiency virus confirmation and care after rapid human immunodeficiency virus self-test: Data from partner services program, New York City. Sexually Transmitted Diseases. 2017;44(10):608–12. Ricca AV, Hall EW, Khosropour CM, Sullivan PS. Factors associated with returning at-home specimen collection kits for HIV testing among internet-using men who have sex with men

2019 Ontario HIV Treatment Network

6. Doravirine for the treatment of HIV-1 in adults

between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities Plain Language Summary About HIV-1 Human immunodeficiency virus (HIV) is a virus that damages a type of white blood cell in the immune system called a CD4 cell. Damaging CD4 cells weakens the body’s ability to fight off infection and disease, leaving people with HIV vulnerable to opportunistic infection. In some cases, this can lead (...) (lamivudine and tenofovir disoproxil). What we have decided NHS England has carefully reviewed the evidence prepared by NICE on treating HIV- 1 with doravirine. We have concluded that there is enough evidence to consider making the treatment available. 1 Introduction Human immunodeficiency virus type 1 (HIV-1) is a virus that damages the CD4 cells of the immune system, leaving the body less able to fight off infection and disease. In some cases the damage caused to the immune system by HIV leads

2019 NHS England

7. Summary of Cervical Cancer Screening Recommendations for Non-HIV Immunocompromised Women

Summary of Cervical Cancer Screening Recommendations for Non-HIV Immunocompromised Women (current immunosuppressants are listed in Table 2). Women with RA and IBD not on immunosuppressants and women with DM were considered at no increased risk compared with the general population. Screening recommendations based on these risks are summarizedinTable3. REFERENCES 1. GrulichAE,vanLeeuwenMT,FalsterMO,etal.Incidence ofcancersin peoplewithHIV/AIDScomparedwithimmunosuppressedtransplant recipients

2019 American Society for Clinical Pathology

8. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

Pathophysiology in HIV: Metabolic Contributors HIV infection is associated with metabolic complications, including dyslipidemia, insulin resistance, and body composition changes, which can contribute to CVD. Initially, dyslipidemia in HIV was characterized by increased triglyceride levels, thought to be related to immunodeficiency in the pre-ART era. Later, specific ART medications, including several protease inhibitors (PIs) and efavirenz, a non–nucleoside reverse transcriptase inhibitor (NRTI), were (...) Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May

2019 American Heart Association

9. Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection

Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection Prescrire IN ENGLISH - Spotlight ''Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection'', 1 November 2019 {1} {1} {1} | | > > > Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Dolutegravir (...) + rilpivirine (Juluca°) dual therapy in HIV infection FEATURED REVIEW First-line therapy for patients with HIV infection is usually based on triple therapy. When sustained virological suppression has been achieved, treatment "simplification" can sometimes be considered. Is the two-drug regimen dolutegravir + rilpivirine (Juluca°) any better than other treatment options? Full review (3 pages) available for download by subscribers. Prescrire's rating NOTHING NEW In patients who have an undetectable viral load

2019 Prescrire

10. Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya Full Text available with Trip Pro

Text messaging for maternal and infant retention in prevention of mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-randomized trial in Kenya Timely diagnosis of infant HIV infection is essential for antiretroviral therapy (ART) initiation. In a randomized controlled trial, we found the Texting Improves Testing (TextIT) intervention (a theory-based text messaging system) to be efficacious for improving infant HIV testing rates and maternal retention in prevention (...) of mother-to-child HIV transmission (PMTCT) programs. Using an implementation science approach, we aimed to evaluate real-world effectiveness of the intervention.In a pragmatic, cluster-randomized, stepped-wedge trial with 2 time periods of observation, we randomly allocated 10 clinics to begin implementing the intervention immediately and 10 clinics to begin implementing 6 months later. To approximate real-world conditions, inclusion criteria were broad. Women at clinics implementing the intervention

2019 EvidenceUpdates

11. Unmet needs of Indigenous peoples living with HIV

Unmet needs of Indigenous peoples living with HIV Unmet needs of Indigenous peoples living with HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Unmet needs of Indigenous peoples living with HIV Unmet needs of Indigenous peoples living with HIV , , , , , , , , , Questions What are the unmet needs of Indigenous peoples living with HIV? What interventions, strategies, and programs have been used to address these needs? Key take-home messages In 2016, First Nations, Métis (...) , and Inuit peoples accounted for 4.9% of the Canadian population but represented 11.3% of all new HIV infections (1). When considering Indigenous health, conventional approaches to HIV and other communicable diseases are insufficient (2). Considerable disconnect exists between the priorities of the HIV care cascade and the experiences of Indigenous peoples living with HIV (3). The lack of coordination between mainstream HIV biomedical approaches and Indigenous worldviews appears to contribute to poor

2019 Ontario HIV Treatment Network

12. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. (Abstract)

Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. The safety, efficacy, and appropriate timing of isoniazid therapy to prevent tuberculosis in pregnant women with human immunodeficiency virus (HIV) infection who are receiving antiretroviral therapy are unknown.In this multicenter, double-blind, placebo-controlled, noninferiority trial, we randomly assigned pregnant women with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated either during

2019 NEJM

13. Dovato - dolutegravir / lamivudine - HIV-1 infection

Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg. Submission Type: New Project Status: Active Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: September 30, 2019 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH (...) Dovato - dolutegravir / lamivudine - HIV-1 infection dolutegravir / lamivudine | CADTH.ca Find the information you need dolutegravir / lamivudine dolutegravir / lamivudine Last Updated: October 3, 2019 Result type: Reports Project Number: SR0601-000 Product Line: Generic Name: dolutegravir / lamivudine Brand Name: Dovato Manufacturer: ViiV Healthcare Indications: HIV-1 infection Manufacturer Requested Reimbursement Criteria 1 : Indicated as a complete regimen for the treatment of Human

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

14. Ibalizumab (Trogarzo) - HIV-1

in the EU What is Trogarzo and what is it used for? Trogarzo is a medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Trogarzo is given with other HIV medicines when none of the standard combinations work to control the infection because the virus is resistant to them (multi-drug resistant HIV). Trogarzo contains the active substance ibalizumab. How is Trogarzo used? The medicine can only be obtained (...) should receive appropriate treatment. For more information about using Trogarzo, see the package leaflet or contact your doctor or pharmacist. How does Trogarzo work? The active substance in Trogarzo, ibalizumab, is a monoclonal antibody (a type of protein) designed to attach to CD4, a receptor (target) found on the surface of immune cells called T cells. T cells are the main target of the HIV virus, which it uses as a host to reproduce. By attaching to CD4, ibalizumab prevents the virus from

2019 European Medicines Agency - EPARs

15. The risk of coercion in the context of HIV self-testing

care, and protection from abuse (2–4). More research is needed on unintended consequences of self-testing in situations where testing is coercive and puts individuals at risk for violence if they refuse (5). The issue and why it’s important There are ethical and human rights concerns with respect to whether HIV self-testing (also known as home-testing or home-based HIV testing) could be used in coercive ways that are harmful to vulnerable people (6). Two areas of particular concern are abusive (...) the test (e.g., losing their job, breaking up a relationship, and not having sex) (7). Alais and Venter (2014) provide their views on ethical, legal and human rights concerns raised by licensing HIV self-testing for private use and argue that HIV self-home tests are not likely to be harmful in a way that justifies restricting people’s access to them, and have plausible benefits (6). At the same time, it is important that reasonably robust protections are in place to protect against coerced testing

2019 Ontario HIV Treatment Network

16. Sexual and reproductive health and HIV: applying All Our Health

Sexual and reproductive health and HIV: applying All Our Health Sexual and reproductive health and HIV: applying All Our Health - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Sexual and reproductive health (...) and HIV: applying All Our Health Evidence and guidance on improving sexual health in communities with contraception, HIV and STI testing and easy access to advice. Published 1 April 2015 Last updated 17 September 2019 — From: Documents HTML Details Examples to inform healthcare professionals and maximise their contribution to health protection by improving sexual health outcomes. Published 1 April 2015 Last updated 17 September 2019 17 September 2019 Updated information on sexual and reproductive

2019 Public Health England

17. Dolutegravir (Tivicay) - HIV-1 (Submission control number 207076)

Dolutegravir (Tivicay) - HIV-1 (Submission control number 207076) Available information for Tivicay - Submission control number 207076 - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Available information for Tivicay - Submission control number 207076 From Content and search results on this site are in the language provided by the manufacturer. Access and use of clinical information is governed by the . Submission information Submission control

2019 Health Canada - drugs and medical devices

18. Dolutegravir (Tivicay) - HIV-1 (Submission control number 192462)

Dolutegravir (Tivicay) - HIV-1 (Submission control number 192462) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf

2019 Health Canada - drugs and medical devices

19. Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. (Abstract)

Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. Accurate diagnosis of tuberculosis in people living with HIV is difficult. HIV-positive individuals have higher rates of extrapulmonary tuberculosis and the diagnosis of tuberculosis is often limited to imaging results. Ultrasound is such an imaging test that is widely used as a diagnostic tool (including point-of-care) in people suspected of having (...) abdominal tuberculosis or disseminated tuberculosis with abdominal involvement.To determine the diagnostic accuracy of abdominal ultrasound for detecting abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals.To investigate potential sources of heterogeneity in test accuracy, including clinical setting, ultrasound training level, and type of reference standard.We searched for publications in any language up to 4 April 2019 in the following databases

2019 Cochrane

20. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. (Abstract)

CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. The safety of CRISPR (clustered regularly interspaced short palindromic repeats)-based genome editing in the context of human gene therapy is largely unknown. CCR5 is a reasonable but not absolutely protective target for a cure of human immunodeficiency virus type 1 (HIV-1) infection, because CCR5-null blood cells are largely resistant to HIV-1 entry. We transplanted CRISPR-edited CCR5-ablated hematopoietic stem (...) and progenitor cells (HSPCs) into a patient with HIV-1 infection and acute lymphoblastic leukemia. The acute lymphoblastic leukemia was in complete remission with full donor chimerism, and donor cells carrying the ablated CCR5 persisted for more than 19 months without gene editing-related adverse events. The percentage of CD4+ cells with CCR5 ablation increased by a small degree during a period of antiretroviral-therapy interruption. Although we achieved successful transplantation and long-term engraftment

2019 NEJM